Navigation Links
MicuRx Completes $25 Million Series B Financing

HAYWARD, Calif. and SHANGHAI, Aug. 22, 2013 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced it raised $25 million in Series B financing. Led by BVCF, a private equity and growth fund specializing in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures.

Proceeds from the Series B financing will be used to fund the U.S. development of MRX-I, a novel oral oxazolidinone antibiotic targeting infections due to multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Weixin Xu and Davis Yang of BVCF will join the MicuRx board of directors.

"We invest in companies with experienced management teams and sound strategic plans," said Zhi Yang, general partner at BVCF. "We look forward to supporting the parallel development of MRX-I in the United States and China, as this novel antibiotic has the potential to offer an attractive option for addressing the growing threat of multi-drug resistant bacteria."

"MicuRx's unusually high capital efficiency in their first six years of operation is exceptional for antibiotic development," commented Zhengyu Yuan, Ph.D., president and chief executive officer of MicuRx Pharmaceuticals, Inc. "Using a US-China hybrid discovery and development model, MicuRx successfully completed design and optimization of its novel oxazolidinone drug candidates and advanced MRX-I through Phase-1 clinical trials with a fraction of the capital required through a traditional operating model in the United States. With the initiation of Phase 2 clinical trials in China, through the joint venture Shanghai MengKe Pharmaceuticals with Shanghai Zhangjiang Biomedical Industry Venture Capital, we look forward to initiating development of MRX-I through a Phase 2 clinical trial at selected centers in the United States, to ensure successful development of this compound internationally. Importantly, BVCF will be an exceptional partner for MicuRx, with broad contacts internationally and extensive healthcare experience to guide our strategic development and commercialization plans."

MRX-I: A Potent and Safe Oxazolidinone Antibiotic
MRX-I is a next-generation oral oxazolidinone antibiotic for treating Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Phase I clinical results demonstrated that MRX-I is safe and well tolerated in human subjects, with no signs of myelosuppression, the major toxicity concern for most oxazolidinone agents, including linezolid. In preclinical studies, MRX-I cures in vivo infections due to Gram-positive bacteria including MRSA and VRE effectively. In addition, MRX-I exhibits two-fold improved activity against MRSA strains as compared to linezolid.

About BVCF
BVCF (, formally known as BioVeda China) is the first and go-to private equity and growth capital investor specializing in China Life Sciences and Healthcare industry. Headquartered in Shanghai, BVCF's team includes partners with premier academic background and extensive operational experience. Investors include institutional limited partners and leading MNC pharmaceutical companies. BVCF focuses on investment in mid-market (US$ 50 – 100 million enterprise value) Life Science and Healthcare companies in China. The BVCF team takes an active approach with all of its investments, through predominantly significant minority ownership position and selected control stake position. The target portfolio company for BVCF is profiled to be a mid to late stage company as a top player in its sector with capable trustworthy management teams and strong growth potential.

About MicuRx Pharmaceuticals, Inc.
MicuRx ( is discovering and developing novel antibiotics to combat infections due to resistant bacteria. Positioned to capture the benefits of United States research and development expertise together with the high quality, cost-efficient discovery, preclinical and development infrastructure in China, the company has built a pipeline of discovery and development programs targeting Gram-positive and Gram-negative pathogens. The company has research and development facilities outside San Francisco, CA in the United States and in Shanghai, China.  MicuRx has raised $12 million in Series A venture funds from Morningside Group ( and Devon Park Bioventures (

SOURCE MicuRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MicuRx Pharmaceuticals Announces Issuance Of U.S. Patent For Its Next-Generation Antibacterial Agent
2. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
3. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
4. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
5. CryoLife Completes Acquisition of Hemosphere
6. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
7. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
8. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
9. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
10. Ablative Solutions Completes $5.3M Series A Financing
11. Quantum OPS Completes $1.05M In Series A Financing To Advance Surgical Devices
Post Your Comments:
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. ... big data solutions, today announced that its MyDario product is expected to ... TV listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
Breaking Medicine News(10 mins):